Neogenomics (NEO) Q3 FY2026 earnings: revenue $209 million, up 11.4% on the year

Neogenomics Inc. (NEO) reported revenue of $209 million for Q3 FY2026, the quarter ended 30 September 2026, up 11.4% on the same quarter a year earlier. Net income was -$8 million, and diluted earnings per share $-0.06. The figures are the company's own, from the 10-Q it filed with the SEC on 28 October 2026.

Revenue$209 millionup 11.4%

Net income-$8 million

Diluted EPS$-0.06

QuarterQ3 FY2026ended 30 September 2026

What management said

Guidance figures: 1 raised, 1 new, 2 kept.

Warren Stone becomes CEO January 4, 2027: Warren Stone, President and COO, appointed as CEO and Board member effective January 4, 2027. Stone brings more than 30 years of life sciences and diagnostics leadership from Ortho Clinical Diagnostics and MilliporeSigma/Merck.
Tony Zook becomes Executive Chairman: Tony Zook transitions from CEO to Executive Chairman effective January 4, 2027, continuing to work with Stone and Board to ensure stability and execution against company objectives.
Succession reflects deliberate Board planning: CEO and Board describe transition as result of years of deliberate succession planning, emphasizing strategic continuity and consistent strategy for durable profitable growth at company.

Read the earnings call summary

The quarter, against the one before and a year earlier

Line	Q3 FY2026	Q2 FY2026	Q3 FY2025	Change on the year
Revenue	209	202	188	+11.4%
Cost of revenue	113	110	107	+5.0%
Gross profit	96.6	91.9	80.4	+20.1%
Gross margin	46.2%	45.6%	42.8%
Research and development	9.9	10.8	8.7	+13.4%
Operating income	-7.9	-9.8	-27.0	n/a
Operating margin	-3.8%	-4.8%	-14.4%
Interest expense	1.3	0.8	0.6	+110.1%
Pre-tax income	-8.0	1.8	-26.4	n/a
Income tax	-0.5	-0.4	0.7	n/a
Effective tax rate	n/a	-22.6%	n/a
Net income	-7.5	2.2	-27.1	n/a
Net margin	-3.6%	1.1%	-14.4%
Diluted EPS	-$0.06	$0.02	-$0.21	n/a

$ million except per share.

Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.

Cash flow and capital returned

Line	Q3 FY2026	Q2 FY2026	Q3 FY2025	Change on the year
Operating cash flow	-8.9	20.0	8.9	n/a
Capital expenditure	11.8	8.2	8.3	+41.6%
Free cash flow	-20.7	11.7	0.6	n/a
Free cash flow margin	-9.9%	5.8%	0.3%
Cash from investing	-11.8	-8.3	-0.3	n/a
Cash from financing	14.5	-12.2	0.8	+1792.2%
Depreciation and amortisation	16.2	16.2	16.4	-1.5%
Share-based compensation	8.8	8.2	10.3	-14.2%
Buybacks	0.0	n/a	0.0	n/a
Diluted shares, weighted	129m	131m	128m	+0.1%
Shares outstanding at period end	129m	128m	129m	+0.2%

Cash flow lines for the quarter; where the company files them year to date, the quarter is the difference between two filings.

Balance sheet at quarter end

Line	Q3 FY2026	Q2 FY2026	Q3 FY2025	Change on the year
Shareholders' equity	801	786	838	-4.5%
Debt	375	374	341	+9.7%
Operating lease liabilities	64.3	64.7	64.3	-0.0%
Finance lease liabilities	4.2	4.0	n/a	n/a
Other liabilities	133	124	131	+1.9%
Total liabilities and equity	1,377	1,352	1,375	+0.2%
Fixed assets	85.9	80.9	85.5	+0.6%
Goodwill	524	524	524	-0.1%
Intangible assets	264	271	294	-10.4%
Cash and equivalents	139	146	164	-15.1%
Receivables	213	175	155	+37.4%
Inventory	25.5	27.1	28.5	-10.4%
Other assets	125	128	123	+1.8%
Total assets	1,377	1,352	1,375	+0.2%

Questions

What was Neogenomics' revenue in Q3 FY2026?

Neogenomics (NEO) reported revenue of $209 million for Q3 FY2026, the quarter ended 30 September 2026, up 11.4% on the same quarter a year earlier.

How much did Neogenomics earn in Q3 FY2026?

Net loss for Q3 FY2026 was $8 million, and the diluted loss per share $0.06.

When did Neogenomics report Q3 FY2026 results?

Neogenomics filed its 10-Q for the quarter ended 30 September 2026 with the SEC on 28 October 2026.

Quarterly results, the last 20 quarters

	Q4 FY2021 *	Q1 FY2022	Q2 FY2022	Q3 FY2022	Q4 FY2022 *	Q1 FY2023	Q2 FY2023	Q3 FY2023	Q4 FY2023 *	Q1 FY2024	Q2 FY2024	Q3 FY2024	Q4 FY2024 *	Q1 FY2025	Q2 FY2025	Q3 FY2025	Q4 FY2025 *	Q1 FY2026	Q2 FY2026	Q3 FY2026
Revenue	126	117	125	129	139	137	147	152	156	156	165	168	172	168	181	188	190	187	202	209
Cost of revenue	80.5	78.9	81.1	79.9	81.9	82.4	87.0	89.6	88.0	90.8	92.0	92.9	94.7	94.8	104	107	107	106	110	113
Gross profit	45.3	38.2	43.9	48.9	56.8	54.8	59.9	62.3	67.6	65.5	72.5	74.9	77.3	73.2	77.3	80.4	83.3	80.9	91.9	96.6
Gross margin	36%	33%	35%	38%	41%	40%	41%	41%	43%	42%	44%	45%	45%	44%	43%	43%	44%	43%	46%	46%
R&D	8.5	7.7	8.6	7.3	6.7	7.4	7.5	5.3	7.1	7.6	7.9	7.7	8.0	10.2	9.0	8.7	9.2	9.5	10.8	9.9
Operating income	-41.6	-52.0	-39.7	-39.5	-26.4	-35.1	-29.9	-24.2	-18.6	-30.6	-21.9	-21.2	-18.4	-27.8	-47.6	-27.0	-13.4	-18.2	-9.8	-7.9
Operating margin	-33%	-44%	-32%	-31%	-19%	-26%	-20%	-16%	-12%	-20%	-13%	-13%	-11%	-17%	-26%	-14%	-7%	-10%	-5%	-4%
Interest expense	1.7	1.3	0.9	0.1	-0.9	1.8	-2.5	-2.8	n/a	1.7	1.7	1.6	1.6	1.6	0.9	0.6	0.6	0.6	0.8	1.3
Pre-tax income	-44.2	-53.2	-41.0	-39.6	-25.5	-33.7	-26.6	-21.5	-15.3	-27.7	-19.0	-17.8	-16.1	-25.7	-45.8	-26.4	-12.4	-17.6	1.8	-8.0
Tax rate	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	-23%	n/a
Net income	-41.8	-49.4	-35.3	-36.9	-22.7	-30.8	-24.3	-18.5	-14.3	-27.1	-18.6	-17.7	-15.3	-25.9	-45.1	-27.1	-9.9	-17.1	2.2	-7.5
Net margin	-33%	-42%	-28%	-29%	-16%	-22%	-17%	-12%	-9%	-17%	-11%	-11%	-9%	-15%	-25%	-14%	-5%	-9%	1%	-4%
Diluted EPS	n/a	-$0.40	-$0.28	-$0.30	-$0.18	-$0.25	-$0.19	-$0.15	-$0.11	-$0.21	-$0.15	-$0.14	-$0.12	-$0.20	-$0.35	-$0.21	-$0.08	-$0.13	$0.02	-$0.06
Operating cash flow	-19.8	-29.0	-17.0	-16.3	-3.7	-12.7	-1.5	-5.5	17.8	-25.9	13.9	9.2	9.8	-25.3	20.3	8.9	1.3	-8.1	20.0	-8.9
Capital expenditure	12.0	8.2	10.3	7.8	4.5	9.9	7.5	4.3	7.1	5.6	13.1	10.8	11.6	4.5	6.3	8.3	7.9	5.0	8.2	11.8
Free cash flow	-31.8	-37.3	-27.3	-24.1	-8.2	-22.6	-9.0	-9.8	10.7	-31.5	0.8	-1.6	-1.8	-29.8	14.0	0.6	-6.5	-13.1	11.7	-20.7
Buybacks	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	0.0	n/a	n/a	n/a	0.0
Shares outstanding	112m	125m	126m	127m	124m	127m	127m	127m	127m	127m	128m	128m	127m	128m	129m	129m	128m	130m	128m	129m
Filing	10-K	10-Q	10-Q	10-Q	10-K	10-Q	10-Q	10-Q	10-K	10-Q	10-Q	10-Q	10-K	10-Q	10-Q	10-Q	10-K	10-Q	10-Q	10-Q

Each quarter as filed, linked to its filing.

* The fourth quarter is the full year less the first three quarters, because the company files the year and not the quarter on its own. A fourth quarter's EPS, and its diluted share count where shown, are from the company's results press release for that quarter, checked against the company's filed figures or a second data source. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and the share count are as they are. Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Cash flow lines filed year to date are the difference between two filings. Shares outstanding are at the period end where the balance sheet tags them, otherwise the count on the filing's cover page. A derived fourth-quarter EPS is left blank when a split in the year makes the arithmetic meaningless.

10-Q for the period ended 30 September 2026, filed 28 October 2026: the filing.